Abstract: The invention relates to a syringe-connector device comprising, in particular, a hollow plunger including an open inner channel, which plunger can move inside a reservoir, said reservoir being open at one end in a distal connection, for the separate administration of controlled quantities of at least two products in a single injection.

Abstract: The present invention relates to novel injectable presentations, kits or syringes comprising a composition with sustained or controlled release of lanreotide or one of the salts thereof. The compositions of lanreotide or one of the salts thereof are packaged in a syringe having a diameter greater than 3.00 mm and provided with a needle having an outer diameter no greater than 1.00 mm.

Abstract: The present invention relates to novel injectable presentations, kits or syringes comprising a composition with sustained or controlled release of lanreotide or one of the salts thereof. The compositions of lanreotide or one of the salts thereof are packaged in a syringe having a diameter greater than 3.00 mm and provided with a needle having an outer diameter no greater than 1.00 mm.

Abstract: The present invention relates to the field of pharmaceutical compositions for ocular diseases, in particular, retinal neurogenerative diseases. The invention provides pharmaceutical compositions to be applied topically in the eyes, including peptides and methods for preparing them thereof. This invention further relates to ophthalmic pharmaceutical composition for use in the topical eye treatment and/or prevention of a retinal neurodegenerative disease.

Abstract: Injectable prolonged-action compositions for use in the treatment of nail diseases, including potentially promoting the growth of the nail, or for use promoting the growth of the nail. The compositions are administered subcutaneously, and optionally as an implant. The compositions may be in solid or non-solid form and include one or more solid biodegradable sustained-release polymers, and optionally one or more active substances.

Abstract: Disclosed is an injection device of the type including a cylindrical body enclosing a reservoir containing a product to be injected, which is slidably mounted in the body, which is open at one end on an injection needle and is closed at its other end by a plunger mounted movable in translation in the reservoir under the action of a plunger rod provided with a control member, the surface of the distal end of the body being coated with adhesive capable of ensuring that this surface is held on the skin of a patient. This device is characterized in that it includes a mechanism for securing the needle, the activation of which is ensured by the adhesive when a withdrawal effort is exerted on the injection device.

Abstract: The present invention relates to novel injectable presentations, kits or syringes comprising a composition with sustained or controlled release of lanreotide or one of the salts thereof. The compositions of lanreotide or one of the salts thereof are packaged in a syringe having a diameter greater than 3.00 mm and provided with a needle having an outer diameter no greater than 1.00 mm.

Abstract: Disclosed is a device for filling the injection device, the injection device of the type including a cylindrical body enclosing a reservoir containing a product to be injected, the reservoir opening at one end on an injection needle and being closed at its other end by a plunger mounted so as to be movable in translation in the reservoir under the control of a plunger rod provided with a control member, the device including a unit for controlling the quantity of product to be delivered. The control unit is arranged on the body in an area located outside an area where the body is intended to be fully gripped by the hand. Also disclosed is a device for filling the injection device.

Abstract: The invention relates to a syringe-connector device comprising, in particular, a hollow plunger including an open inner channel, which plunger can move inside a reservoir, said reservoir being open at one end in a distal connection, for the separate administration of controlled quantities of at least two products in a single injection.

Abstract: The present invention relates to a parenteral, sustained and controlled release, semisolid formulation comprising an end-capped oligomer and at least one active substance without any supplementary viscosity reducing agent or excipient.

Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.

Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.

Abstract: A catalytic lactide and glycolide copolymerization system comprising a trifluoromethane sulfonate as a catalyst and copolymerization additive and a copolymerization process.

Abstract: The present invention relates to a parenteral, sustained and controlled release, semisolid formulation comprising an end-capped oligomer and at least one active substance without any supplementary viscosity reducing agent or excipient.

Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.

Abstract: The present invention is directed to pharmaceutical composition comprising a clear solution or an aqueous mixture, a suspension or a semisolid of at least one peptide compound selected from the group consisting of hGLP-1(7-36)-NH2 and analogs and derivatives thereof, hGLP-1(7-37)-OH and analogs and derivatives thereof and/or exendin-4 and analogs and derivatives thereof, zinc and solvent wherein at least 95% of the said peptide compound is dissolved by the solvent.

Abstract: A catalytic lactide and glycolide copolymerization system comprising a trifluoromethane sulfonate as a catalyst and copolymerization additive and a copolymerization process.

Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.

Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.

Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.